Trulicity Injection, Solution
Product Images NDC 0002-2236

Product Visual Gallery

This gallery contains 53 technical images submitted to the FDA as part of the official labeling for Trulicity (NDC 0002-2236). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Trulicity Pi F1 V2)

A forest plot chart depicting pharmacokinetic (PK) parameters AUC and Cmax ratios with 90% confidence intervals relative to reference for Trulicity (Dulaglutide). It compares intrinsic factors including weight, age, gender, race, renal impairment, and hepatic impairment, showing their effect on drug exposure ratios.*

FDA Label Image

Figure 2 (Trulicity Pi F2 V2)

A chart showing pharmacokinetic ratios and 90% confidence intervals (CI) for various coadministered drugs relative to a reference. The chart lists drugs on the left including Lisinopril, Metoprolol, Digoxin, Norelgestromin, Ethinylestradiol, Atorvastatin, Metformin, Acetaminophen, S-Warfarin, R-Warfarin, and Sitagliptin, with parameters AUC and Cmax. The x-axis shows the ratio relative to reference, ranging from 0.0 to 2.0, with data points represented as diamond shapes with error bars for each drug and parameter.*

FDA Label Image

Figure 3 (Trulicity Pi F3 V3)

A line graph comparing the least squares mean HbA1c (%) over 52 weeks post-randomization for treatments including Trulicity 0.75 mg, Trulicity 1.5 mg, Sitagliptin 100 mg, and placebo. The graph shows changes in HbA1c levels over time, with Trulicity doses generally producing greater reductions compared to Sitagliptin and placebo.*

FDA Label Image

Figure 4 (Trulicity Pi F4 V3)

A line chart depicting the mean HbA1c percentage over weeks post-randomization for Trulicity injection in 1.5 mg, 3 mg, and 4.5 mg strengths. The chart shows data points from baseline to week 36, illustrating changes in mean HbA1c levels across these dosage groups.*

FDA Label Image

Figure 5 (Trulicity Pi F5 V2)

A line graph depicting the least squares mean HbA1c percentage over 26 weeks post-randomization for Trulicity 1.5 mg, Trulicity 0.75 mg, Exenatide, and placebo groups. The x-axis shows weeks post-randomization (0, 13, 26), and the y-axis shows LS mean HbA1c (%). The graph illustrates changes in HbA1c levels for each group during the study period.*

FDA Label Image

Figure 6 (Trulicity Pi F6 V2)

A Kaplan-Meier curve chart comparing the percentage of patients with an event over approximately six years between Dulaglutide and placebo groups. The x-axis represents time from randomization in years, and the y-axis shows the percentage of patients with an event. The Dulaglutide group shows a slightly lower event rate than placebo, with a hazard ratio of 0.88 and 95% confidence interval [0.79, 0.99].*

FDA Label Image

Figure (Trulicity Ifu Unfold V1)

Instructional diagram illustrating how to unfold an informational leaflet. The image directs consumers to unfold the leaflet flat and read both sides for complete instructions. This type of diagram commonly accompanies medication packaging to guide users on accessing detailed information.*

FDA Label Image

Logo (Logo)

FDA Label Image

Figure (Trulicity Ifu Remove V1)

FDA Label Image

Figure (Trulicity Ifu Check V1)

FDA Label Image

Figure (Trulicity Ifu Inspect V1)

FDA Label Image

Figure (Trulicity Ifu Prepare V1)

An instructional illustration depicting a hand under running water with two water droplets falling from above, representing the action of hand washing or rinsing as part of a hygiene or preparation step.*

FDA Label Image

Figure (Trulicity Ifu 0point75 Injection Sites Front V1)

Illustration showing an outline of a human torso and upper legs highlighting recommended subcutaneous injection sites for Trulicity (Dulaglutide) in yellow, including the abdomen area around the navel and the outer thighs.*

FDA Label Image

Figure (Trulicity Ifu 0point75 Injection Sites Back V1)

An instructional illustration showing the human body from the back with yellow highlighted areas on both upper arms, indicating preferred injection sites for a subcutaneous injection.*

FDA Label Image

Qr Code (Qr V1)

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen V3)

Trulicity injection pen containing Dulaglutide solution for subcutaneous use. The pen label features purple, yellow, and white colors with dosing indicator windows, and the cap is green. The product is manufactured by Eli Lilly and Company.*

FDA Label Image

Figure (Trulicity Ifu Expiration Location V2)

Trulicity injection pen cap showing an expiration date window. The visible part highlights the expiration date indicator on the pen, which is used for subcutaneous administration of Dulaglutide by Eli Lilly and Company.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen Parts V3)

An instructional diagram of a Trulicity (Dulaglutide) injection pen illustrating key parts, including the green Injection Button, white Lock Ring, Indicator, Lock/Unlock symbols, the Medicine chamber, Clear Base, and Base Cap at the bottom/needle end. The pen is oriented with the top at the Injection Button and the bottom at the needle end.*

FDA Label Image

Locked (Trulicity Ifu Locked V1)

Trulicity injection, solution for subcutaneous use in a prefilled pen, available in strengths of 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, and 4.5 mg/0.5 mL. The label displays the proprietary name "Trulicity" with the active ingredient dulaglutide, manufactured by Eli Lilly and Company.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F2 V3)

An instructional illustration showing a hand holding a Trulicity (Dulaglutide) injection pen, poised above a black circular cap held by another hand. A purple arrow indicates the motion of removing or detaching the cap from the injection pen. This diagram is likely part of the usage or preparation instructions for the subcutaneous injection of Trulicity by Eli Lilly and Company.*

FDA Label Image

Unlocked (Trulicity Ifu Unlock V1)

Trulicity injection, solution prefilled pen label for subcutaneous use, showing dosage strength of 4.5 mg per 0.5 mL. The label includes storage instructions, a lot number, expiration date, and manufacturer information, Eli Lilly and Company.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F3 V3)

An instructional illustration showing hands preparing a Trulicity (dulaglutide) prefilled injection pen for subcutaneous use. The image highlights the removal of a protective cap or shield from the green-tipped injection device, indicating steps to ready the medication for administration.*

FDA Label Image

Exclamation (Trulicity Ifu Exclamation V1)

Trulicity injection, solution for subcutaneous use by Eli Lilly and Company, shown in a carton displaying four different strengths: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, and 4.5 mg/0.5 mL. The packaging is white with color-coded labels for each strength.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F4 V3)

An instructional illustration showing the technique for administering a subcutaneous injection with the Trulicity injection pen. It depicts a person holding the pen in place on the skin for 5 to 10 seconds after injection and includes a close-up detail of the pen's indicator window to verify completion.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F5 V3)

An instructional illustration showing a hand holding a pre-filled Trulicity (dulaglutide) injection pen above a sharps disposal container marked with a biohazard symbol, indicating safe needle disposal.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen V3)

Trulicity injection, solution in a single-dose, pre-filled pen injector. The device is primarily white with a blue and purple design panel and a green dose button at the end. The pen is designed for subcutaneous administration and labeled by Eli Lilly and Company.*

FDA Label Image

Figure (Trulicity Ifu 1point5 Injection Sites Front V1)

An illustration showing a front view of a human torso and upper legs with blue shaded areas indicating recommended injection sites. The highlighted areas are on the abdomen around the navel and the front middle section of both thighs.*

FDA Label Image

Figure (Trulicity Ifu 1point5 Injection Sites Back V1)

An instructional diagram showing a rear view of a human figure with blue shaded areas on the outer upper arms, indicating preferred sites for subcutaneous injection administration.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen Parts V3)

An illustration diagram of a Trulicity (dulaglutide) injection pen labeled with parts including Injection Button, Lock Ring, Indicator, Lock/Unlock symbols, Medicine chamber, Clear Base, and Base Cap. Directions indicating the Top and Bottom/Needle End are also shown.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F2 V3)

An instructional diagram showing a hand holding a Trulicity injection pen (solution for subcutaneous injection). The illustration indicates removal of a black cap from the pen, with a downward arrow highlighting the direction to pull the cap off, likely as part of the injection preparation process.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F3 V3)

An instructional diagram showing a person preparing a Trulicity injection device for subcutaneous administration. The hands are holding the pen injector with an arrow indicating the removal of a protective cap before injection, suggesting the step to unlock or prepare the device for use.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F4 V3)

An instructional illustration showing a person holding a Trulicity injection pen, demonstrating how to press and hold the pen against the skin for 5 to 10 seconds. A close-up inset highlights the pen's needle area during injection. This visual guides proper subcutaneous administration technique for Trulicity (dulaglutide) injection solution.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F5 V3)

An instructional illustration showing a hand holding a prefilled syringe for subcutaneous injection, positioned above a sharps disposal container marked with a biohazard symbol. The image relates to the safe disposal of used injection devices, relevant to Trulicity (dulaglutide) injection, solution, offered by Eli Lilly and Company.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen V1)

Trulicity injection pen device for subcutaneous use, containing Dulaglutide. The pen is primarily white with a green end cap and a clear section showing the injection mechanism. It features a purple and blue label band with small red and green indicator symbols, consistent with a prefilled injectable solution by Eli Lilly and Company.*

FDA Label Image

Figure (Trulicity Ifu 3mg Injection Sites Front V1)

An anatomical illustration highlighting recommended subcutaneous injection sites on the human body for a drug like Trulicity. The diagram shows shaded areas on the abdomen and both thighs where injections can be administered.*

FDA Label Image

Figure (Trulicity Ifu 3mg Injection Sites Back V1)

Illustration showing the recommended injection sites for Trulicity (dulaglutide) solution. Shaded areas indicate the outer upper arms as appropriate subcutaneous injection sites for this medication.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen Parts V1)

An instructional diagram of a Trulicity injection pen identifying its key components. Labeled parts include the Injection Button, Lock Ring, Indicator, Lock/Unlock mechanism, Medicine reservoir, Clear Base, and Base Cap at the needle end.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F2 V1)

An instructional illustration showing hands manipulating a Trulicity injection pen and its needle cap. The image demonstrates holding the injection pen with one hand and removing the needle cap with the other, indicated by a downward arrow, outlined with a red border and a lock icon.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F3 V1)

An instructional illustration showing hands preparing a Trulicity (Dulaglutide) injection device for subcutaneous administration. The image depicts twisting or unlocking the green cap of the injection pen prior to use.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F4 V1)

Illustration depicting the subcutaneous injection technique for Trulicity (Dulaglutide) injection, solution. It shows a hand holding the injection pen against the thigh, indicating to hold for 5-10 seconds. A close-up inset highlights the gray plunger becoming visible as confirmation that the injection is complete.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F5 V1)

Illustration showing a hand holding a prefilled Dulaglutide injection pen above a biohazard sharps container, demonstrating safe disposal of the injectable pen after use.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen V1)

Trulicity injection pen device for subcutaneous use, containing dulaglutide. The pen features a clear medication window, a gray cap at one end, and purple, white, and green coloring on the body. It is manufactured by Eli Lilly and Company and available in multiple strengths including 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, and 4.5 mg/0.5 mL.*

FDA Label Image

Figure (Trulicity Ifu 4point5mg Injection Sites Front V1)

Illustration showing suitable subcutaneous injection sites for Trulicity (dulaglutide) on a human body. Highlighted areas include the abdomen around the navel and the front of the thighs, indicating recommended injection locations.*

FDA Label Image

Figure (Trulicity Ifu 4point5mg Injection Sites Back V1)

An anatomical illustration showing the back view of a human figure highlighting the upper outer areas of both arms, shaded green, indicating potential injection sites for subcutaneous administration of the injection solution.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen Parts V1)

Illustration of a Trulicity (Dulaglutide) injection pen showing labeled parts: Injection Button at the top, Lock Ring below it, Indicator and Lock/Unlock symbols on the body, Medicine section visible through the Clear Base, with the Base Cap at the bottom which is the needle end.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F2 V1)

An instructional illustration showing how to administer Trulicity (Dulaglutide) injection. It depicts a hand holding the autoinjector pen and another hand removing or preparing a component, with a purple arrow indicating downward movement, likely demonstrating the injection step or preparation of the injection device.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F3 V1)

An instructional illustration showing hands preparing a Trulicity (dulaglutide) injection device for subcutaneous use. The image demonstrates the step of twisting the green cap off the autoinjector prior to injection.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F4 V1)

An instructional diagram illustrating the correct technique to use the Trulicity injection pen. It shows a hand holding the pen against the skin, pressing the injection button for 5-10 seconds. A magnified view highlights the gray plunger, indicating that the injection is complete when the gray plunger is visible.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F5 V1)

An instructional illustration showing a hand holding a syringe above a biohazard sharps disposal container. The image emphasizes proper disposal of used syringes in a designated biohazard container.*

FDA Label Image

Package Label – Trulicity™, 1.5 mg/0.5 mL, Prefilled Syringes, 4 Count (Us Trulicity Sup Point75mg 004 05)

Packaging label for Trulicity (dulaglutide) injection, 0.75 mg/0.5 mL strength, supplied as 4 single-dose pens. The label shows the subcutaneous injection dosage form and indicates once weekly use. Manufacturer is Eli Lilly and Company. The label includes product name, strength, quantity, and usage instructions.*

FDA Label Image

Package Label – Trulicity™, 1.5 mg/0.5 mL, Prefilled Pen, 4 Count (Us Trulicity Sup 1point5mg 005 05)

Trulicity 1.5 mg/0.5 mL injection solution packaging label for subcutaneous use by Eli Lilly and Company. The label indicates a box containing 4 single-dose pens, each delivering a 1.5 mg dose of dulaglutide for once-weekly use. The design features purple, blue, and white colors with dosage and usage instructions clearly marked.*

FDA Label Image

Package Label – Trulicity™, 3 mg/0.5 mL, Prefilled Pen, 4 Count (Us Trulicity Sup 3mg 055 02)

Trulicity 3 mg/0.5 mL injection solution in a single-dose pen for subcutaneous use. The packaging label shows a box containing 4 single-dose pens, each delivering a 3 mg dose, intended for once-weekly use. The labeler is Eli Lilly and Company. The box features purple and white design elements, with instructions to dispense the accompanying medication guide included.*

FDA Label Image

Package Label – Trulicity™, 4.5 mg/0.5 mL, Prefilled Pen, 4 Count (Us Trulicity Sup 4point5mg 056 02)

Trulicity 4.5 mg/0.5 mL injection solution for subcutaneous use in single-dose pens. The label displays packaging for 4 single-dose pens, each delivering a 4.5 mg dose once weekly. The labeler is Eli Lilly and Company, with branding in purple and green accents on a white background.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.